Le Lézard
Classified in: Health
Subjects: SVY, EGV

Two Day Veterinary Pharmaceutical Submissions in the EU Course: London, United Kingdom - November 20-21, 2018


DUBLIN, May 11, 2018 /PRNewswire/ -- The "Veterinary Pharmaceutical Submissions in the EU" conference has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

Presentations will cover the regulatory framework, pharmaceutical, toxicological and pharmacological data, safety risk assessments, pre-clinical and clinical data, Detailed and Critical Summaries and regulatory submissions

Course Overview

This practical two-day In-house course will take participants through all of the constituent parts of the application for marketing authorisation for a veterinary medicinal product for which a marketing authorisation is sought in the European Union, including the Maximum Residue Limits dossier.

Presentations will cover the regulatory framework, pharmaceutical, toxicological and pharmacological data, safety risk assessments, pre-clinical and clinical data, Detailed and Critical Summaries and regulatory submissions. An important part of the course will be devoted to working on case studies in the workshop sessions. The course will provide a comprehensive introduction to the entire regulatory dossier for a veterinary medicinal product in the European Union.

BENEFITS OF ATTENDING

Who Should Attend:

Personnel working in the following departments: Regulatory Affairs, Research and Development and Clinical Trials and Marketing. It will also be valuable to those seeking to review special problems encountered in the registrations of veterinary medicines. There will be ample opportunity for discussion during the proceedings.

Agenda:

Programme Day One

09.30 Introduction and Objectives of the course

09.45 EU Regulatory Framework

10.45 Refreshments

11.00 Part II: Pharmaceutical Data Requirements

12.15 Discussion

12.30 Lunch

13.30 Workshop session

Planning a dossier to contain:

14.45 Part IIIA: Consumer and Environmental Safety Data Requirements

15.15 User Safety Risk Assessment

15.45 Refreshments

16.00 Pharmacokinetics and Bioequivalence

17.00 End of Day One

Programme Day Two

09.00 Environmental Risk Assessment

09.30 Part IIIB Residues

10.15 Safety and Residues' Detailed and Critical Summaries

10.30 Refreshments

10.45 Part IV Pre-Clinical Data

11.15 Part IV Clinical Data and Clinical' Detailed and Critical Summary

11.45 EU Regulatory Strategies and Procedures

12.30 Lunch

14.00 Workshop Session

15.00 Refreshments

15.15 Workshop Presentations

15.45 Writing the Regulatory Submission

16.45 Discussion

17.00 End of Course

For more information about this conference visit https://www.researchandmarkets.com/research/jj3kn8/two_day?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 08:30
Immunome, Inc. , a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D., to its Board of Directors. Dr. Swain has over 30 years of oncology...

at 08:22
The Quest Diagnostics Foundation today announced an expanded collaboration with Green Bronx Machine (GBM), a transformational educational nonprofit...

at 08:07
Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life science pioneers, has released a comprehensive contract research organization (CRO) offering tailor-made for sponsors looking to bring diagnostic products...

at 08:05
Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today the enrollment of the first patient in a pilot study collecting patient-generated health data (PGHD) during proton radiotherapy for lung cancer in...

at 08:05
Roivant and Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and autoimmune diseases, today announced the successful completion of enrollment in its Phase 2 study evaluating namilumab for...

at 08:05
Revvity, Inc. will present at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024 at 8:40 a.m. PT in Las Vegas, NV. Senior Vice President and Chief Financial Officer Max Krakowiak will provide an update on the Company and its...



News published on and distributed by: